Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03138096
Other study ID # PbVac
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date May 29, 2017
Est. completion date October 3, 2018

Study information

Verified date March 2017
Source Radboud University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In the underlying study, a genetically modified P. berghei parasite is used. P. berghei is one of the four Plasmodium species that causes malaria in rodents. The hypothesis is that immunization of humans with P. berghei will induce a cross-species immune response without the risk of a breakthrough infection. To further increase the potential for protective efficacy, the P. falciparum circumsporozoite (CS)- protein gene has been integrated in the P. berghei parasite, generating a genetically modified P. berghei parasite, abbreviated as Pb(PfCS@UIS4).


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date October 3, 2018
Est. primary completion date March 28, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: 1. Subject is aged = 18 and = 35 years and in good health. 2. Subject has adequate understanding of the procedures of the study and is able and willing (in the investigator's opinion) to comply with all study requirements. 3. Subject is willing to complete an informed consent questionnaire and is able to answer all questions correctly. 4. Subject is able to communicate well with the investigator and is available to attend all study visits, lives in Rotterdam or in proximity to the trial centre (can be on site within 1 hour) or is willing to stay in a hotel close to the trial centre during part of the study (phase 1: from day of immunization to day 12 post-immunization; phase 2: from day of immunization to day 8 post-immunization. 5. The subject will remain within the Netherlands from day -1 until day +28 after immunization during phase 1; from day -1 until day 12 after each immunization during phase 2, and during the challenge period, will not travel to a malaria-endemic area during the study period, and is reachable (24/7) by mobile telephone throughout the entire study period. 6. Subject agrees to their general practitioner being informed and contacted about their participation in the study and agrees to sign a form to request the release by their General Practitioner (GP), and medical specialist when necessary, to the investigator(s), of any relevant medical information concerning possible contra-indications for participation in the study. 7. The subject agrees to refrain from blood donation to Sanquin or for other purposes throughout the study period and for a defined period thereafter according to current Sanquin guidelines (3 years minimum, depending on serology). 8. For female subjects: subject agrees to use continuous adequate contraception** and not to breastfeed for the duration of study. 9. Subject agrees to refrain from intensive physical exercise (disproportionate to the subject's usual daily activity or exercise routine) during the malaria challenge period. 10. Subject agrees to avoid additional triggers that may cause elevations in liver enzymes including alcohol from baseline up to 1 week post treatment. 11. Subject has signed written informed consent to participate in the trial. Exclusion Criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: 1. Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine, malignant, haematological, infectious, immunodeficient, psychiatric and other disorders, which could compromise the health of the volunteer during the study or interfere with the interpretation of the study results. These include, but are not limited to, any of the following. 1.1. Body weight <50 kg or Body Mass Index (BMI) <18 or >30 kg/m2 at screening. 1.2. A heightened risk of cardiovascular disease, as determined by: an estimated ten year risk of fatal cardiovascular disease of =5% at screening, as determined by the Systematic Coronary Risk Evaluation (SCORE); history, or evidence at screening, of clinically significant arrhythmia's, prolonged QT-interval or other clinically relevant ECG abnormalities; or a positive family history of cardiac events in 1st or 2nd degree relatives <50 years old. 1.3. A medical history of functional asplenia, sickle cell trait/disease, thalassaemia trait/disease or G6PD-deficiency. 1.4. History of epilepsy in the period of five years prior to study onset, even if no longer on medication. 1.5. Screening tests positive for Human Immunodeficiency Virus (HIV), active Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) 1.6. Chronic use of i) immunosuppressive drugs, ii) antibiotics, iii) or other immune modifying drugs within three months prior to study onset (inhaled and topical corticosteroids and oral anti-histamines exempted) or expected use of such during the study period. 1.7. Any recent or current systemic therapy with an antibiotic or drug with potential anti-malarial activity (chloroquine, atovaquone-proguanil, arthemether-lumefantrine, sulfadoxine-pyrimethamine, doxycycline, tetracycline, piperaquine, benzodiazepine, flunarizine, fluoxetine, tetracycline, azithromycin, clindamycin, erythromycin, hydroxychloroquine, etc.) (allowable timeframe for use at the Investigator's discretion). 1.8. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years. 1.9. Any history of treatment for severe psychiatric disease by a psychiatrist in the past year. 1.10. History of drug or alcohol abuse interfering with normal social function in the period of one year prior to study onset, positive urine toxicology test for cocaine or amphetamines at screening or at inclusion, or positive urine toxicology test for cannabis at inclusion. 2. For female subjects: positive urine pregnancy test at screening and/or at the baseline visits, including baseline of immunizations (I-1) and or baseline before CHMI (C-1). 3. Any history of malaria, positive serology for P. falciparum, or previous participation in any malaria (vaccine) study. 4. Known hypersensitivity to or contra-indications (including co-medication) for use of sulfadoxine-pyrimethamine, piperaquine, chloroquine, Malarone®, artemether-lumefantrine, primaquine or history of severe (allergic) reactions to mosquito bites. 5. Receipt of any vaccinations in the 3 months prior to the start of the study or plans to receive any other vaccinations during the study period or up to 8 weeks thereafter. 6. Participation in any other clinical study in the 30 days prior to the start of the study or during the study period. 7. Being an employee or student of the department of Medical Microbiology and Infectious Diseases of the Erasmus MC or Radboudumc, or the department of Internal Medicine of the Radboudumc or Havenziekenhuis. 8. Any other condition or situation that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Pb(PfCS@UIS4)-infected mosquitoes
Pb(PfCS@UIS4)-infected mosquitoes
Other:
Challenge infection P. falciparum
Challenge infection with bites of five infected Pf mosquitoes

Locations

Country Name City State
Netherlands Radboud university medical center Nijmegen Gelderland
Netherlands Havenziekenhuis Rotterdam

Sponsors (4)

Lead Sponsor Collaborator
Radboud University Medical Center Erasmus Medical Center, Havenziekenhuis, The PATH Malaria Vaccine Initiative (MVI)

Country where clinical trial is conducted

Netherlands, 

References & Publications (1)

Reuling IJ, Mendes AM, de Jong GM, Fabra-García A, Nunes-Cabaço H, van Gemert GJ, Graumans W, Coffeng LE, de Vlas SJ, Yang ASP, Lee C, Wu Y, Birkett AJ, Ockenhouse CF, Koelewijn R, van Hellemond JJ, van Genderen PJJ, Sauerwein RW, Prudêncio M. An open-lab — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Cellular Immune Responses After Exposure to Pb(PfCS@UIS4) [Exploratory Endpoint] Cellular immune responses after repeated exposure to Pb(PfCS@UIS4), as determined by increase in %-age IFNg+ lymphocytes following in vitro stimulation of PBMCs with WT P. falciparum sporozoites measured by flow cytometry at baseline and following immunization (day prior to CHMI) Group 3: from baseline until day prior to CHMI (approximately 15 weeks after first Pb(PfCS@UIS4) immunization)
Other Humoral Immune Responses After Exposure to Pb(PfCS@UIS4) [Exploratory Endpoint] Humoral immune responses after repeated exposure to Pb(PfCS@UIS4) as determined by increase in %-age inhibition of WT P. falciparum sporozoite invasion in HC-04 cells by purified plasma IgG collected at baseline and following immunization (day prior to CHMI). Group 3: from baseline until day prior to CHMI (approximately 15 weeks after first Pb(PfCS@UIS4) immunization)
Primary Adverse Events in Study Groups Following Exposure to Pb(PfCS@UIS4)-Infected Mosquitoes [Safety] Frequency and magnitude of adverse events in study groups following one or more exposures to Pb(PfCS@UIS4)-infected mosquitoes. Groups 1&2: from exposure to Pb(PfCS@UIS4)-infected mosquitoes until 28 days thereafter. Group 3: from first exposure until 21 days after fourth/final exposure (=until day immediately prior to CHMI, i.e. approximately 15 weeks after first exposure).
Primary Presence of Breakthrough Parasitemia Following Exposure to Pb(PfCS@UIS4)-Infected Mosquito Bites Presence of breakthrough parasitemia following (first) exposure to Pb(PfCS@UIS4)-infected mosquito bites, as determined by thick blood smear microscopy Groups 1-3: from (first) exposure until 28 days thereafter.
Primary Time to Parasitemia After CHMI [Efficacy] Time to parasitemia after CHMI with the wild-type NF54 P. falciparum strain, as detected by qPCR [Efficacy] Groups 3&4: from day of CHMI until 28 days thereafter
Secondary Immunogenicity of Pb(PfCS@UIS4) as Assessed by ELISA Immunogenicity of repeated Pb(PfCS@UIS4) immunization as assessed by fold change in anti-P. falciparum IgG from baseline to post-immunization (day prior to CHMI), as measured by ELISA. Group 3: from baseline until day prior to CHMI (approximately 15 weeks after first Pb(PfCS@UIS4) immunization)
See also
  Status Clinical Trial Phase
Terminated NCT04130282 - VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine Phase 1
Completed NCT04049916 - Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission Phase 2/Phase 3
Active, not recruiting NCT03814616 - Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections Phase 2
Active, not recruiting NCT04079621 - Short Course Radical Cure of P. Vivax Malaria in Nepal Phase 4
Completed NCT05135273 - Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali Phase 1
Not yet recruiting NCT06083688 - Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi Phase 4
Recruiting NCT03511443 - Evaluation of the Performance of a hsRDT Versus cRDT in Reactive Case Detection of Malaria Infections N/A
Completed NCT05550909 - Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali Phase 2
Recruiting NCT05306067 - Plasmodium Falciparum Genomic Intelligence in Mozambique
Completed NCT05081089 - Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali Phase 2
Recruiting NCT05150808 - Vectron T500 (Broflanilide 50WP) for IRS in Tanzania Tanzania Phase 3
Recruiting NCT05757167 - Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics Phase 4
Completed NCT01992900 - A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria Phase 2
Completed NCT04565184 - Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde Phase 4
Completed NCT03896724 - Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso Phase 1/Phase 2
Completed NCT03454048 - Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2 N/A
Recruiting NCT04844905 - Adjunctive Ivermectin Mass Drug Administration for Malaria Control Phase 3
Recruiting NCT04271306 - Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania. Phase 1
Recruiting NCT05058885 - Plasmodium Vivax Among Duffy Negative Population in Cameroon.
Completed NCT04862416 - Safety and Efficacy of R0.6C Vaccine Phase 1